At Sanavia, we’re committed to developing targeted solutions for every patient, no matter what cancer they have or where they are in their journey.
At Sanavia, we’re committed to developing targeted solutions for every patient, no matter what cancer they have or where they are in their journey.
If you’re one of the 80% who are searching for medicines that could give you a chance, we’re fighting to keep you healthy.
What if your cancer treatment stopped working? Starting over with a new drug almost always brings fear and uncertainty.
So we’re focused on developing breakthrough therapies that can offer real hope, no matter where you are in the fight.
What if your cancer treatment stopped working? Starting over with a new drug almost always brings fear and uncertainty.
So we’re focused on developing breakthrough therapies that can offer real hope, no matter where you are in the fight.
Traditional R&D takes over 10 years to get drugs to market.
That’s simply not fast enough.
We’re combining immunology with AI and machine learning to slash that time and fast-track safer, more effective drugs to the patients who need them most.
Traditional R&D takes over 10 years to get drugs to market.
That’s simply not fast enough.
We’re combining immunology with AI and machine learning to slash that time and fast-track safer, more effective drugs to the patients who need them most.
Our passionate team of immunologists, structural biologists, drug developers, and AI scientists hail from top institutions including Rockefeller University, Memorial Sloan Kettering Cancer Center, Columbia University and Weill Cornell Medicine.
And, we have pharma veterans on our advisory board who inspire and provide us with decades of unmatched expertise and guidance.
Our passionate team of immunologists, structural biologists, drug developers, and AI scientists hail from top institutions including Rockefeller University, Memorial Sloan Kettering Cancer Center, Columbia University and Weill Cornell Medicine.
And, we have pharma veterans on our advisory board who inspire and provide us with decades of unmatched expertise and guidance.
We're developing antibody drug conjugate (ADC), bispecific T cell engager (TCE) and CAR-T cell therapies that target novel and stable, first-in-class epitopes in validated cancer targets, offering more powerful treatments and giving more patients a better chance to fight cancer.
We're developing antibody drug conjugate (ADC), bispecific T cell engager (TCE) and CAR-T cell therapies that target novel and stable, first-in-class epitopes in validated cancer targets, offering more powerful treatments and giving more patients a better chance to fight cancer.
Our platform has proven it can uncover novel, high-quality drug candidates with greater speed and more precision than ever before. Our more thoughtful approach doesn’t just accelerate the timeline; it’s increasing the chances for success while reducing the cost and risk of typical early-stage R&D. The result: more shots on goal, smarter resource allocation, and higher ROI for biotech partners and investors alike.
Our platform has proven it can uncover novel, high-quality drug candidates with greater speed and more precision than ever before. Our more thoughtful approach doesn’t just accelerate the timeline; it’s increasing the chances for success while reducing the cost and risk of typical early-stage R&D. The result: more shots on goal, smarter resource allocation, and higher ROI for biotech partners and investors alike.
Our platform uncovers novel, target-specific epitopes and therapies—across any indication. Whether you're advancing an internal pipeline or exploring new ground, we’re built to accelerate your discovery. Let’s work together to unlock what’s next.
Our platform uncovers novel, target-specific epitopes and therapies—across any indication. Whether you're advancing an internal pipeline or exploring new ground, we’re built to accelerate your discovery. Let’s work together to unlock what’s next.
Over 18 million Americans battle some form of cancer every day. We’re pushing treatments forward to turn small gains into real breakthroughs that can benefit us all.
Over 18 million Americans battle some form of cancer every day. We’re pushing treatments forward to turn small gains into real breakthroughs that can benefit us all.
Built to take on and tackle the hardest problems in medicine, our immunology driven AI platform helps accelerate scientific breakthroughs to help as many patients as possible.
Built to take on and tackle the hardest problems in medicine, our immunology driven AI platform helps accelerate scientific breakthroughs to help as many patients as possible.
Our scalable foundation helps us rapidly take multiple shots on goal, so we can improve cancer patients’ experiences and outlooks tremendously faster than ever before.
Our scalable foundation helps us rapidly take multiple shots on goal, so we can improve cancer patients’ experiences and outlooks tremendously faster than ever before.
Our team of top scientists from Rockefeller University, Memorial Sloan Kettering Cancer Center, Columbia University, and Weill Cornell Medicine is guided by an advisory board that includes pharma veterans who bring unmatched expertise in immunology, drug development, and AI.
We’re supported by Two Bear Capital, a venture capital firm committed to bold, science-driven companies at the intersection of biology and technology, focused on reshaping industries and improving lives.
Our team of top scientists from Rockefeller University, Memorial Sloan Kettering Cancer Center, Columbia University, and Weill Cornell Medicine is guided by an advisory board that includes pharma veterans who bring unmatched expertise in immunology, drug development, and AI.
We’re supported by Two Bear Capital, a venture capital firm committed to bold, science-driven companies at the intersection of biology and technology, focused on reshaping industries and improving lives.